ES2284681T3 - Epitopos de oligosacaridos del nucleo de lipopolisacaridos de maemophilus influenzae como vacunas para la prevencion de infecciones por haemophilus influenzae. - Google Patents

Epitopos de oligosacaridos del nucleo de lipopolisacaridos de maemophilus influenzae como vacunas para la prevencion de infecciones por haemophilus influenzae. Download PDF

Info

Publication number
ES2284681T3
ES2284681T3 ES01964789T ES01964789T ES2284681T3 ES 2284681 T3 ES2284681 T3 ES 2284681T3 ES 01964789 T ES01964789 T ES 01964789T ES 01964789 T ES01964789 T ES 01964789T ES 2284681 T3 ES2284681 T3 ES 2284681T3
Authority
ES
Spain
Prior art keywords
lps
glcp
galp
strain
lipopolysaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01964789T
Other languages
English (en)
Spanish (es)
Inventor
James C. Richards
Andrew Cox
Richard Moxon
Derek Institute of Molecular Medicine HOOD
Elke K. H. Schweda
Martin Mansson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Sanofi Pasteur SA
Original Assignee
Aventis Pasteur Ltd
Aventis Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur Ltd, Aventis Pasteur SA filed Critical Aventis Pasteur Ltd
Application granted granted Critical
Publication of ES2284681T3 publication Critical patent/ES2284681T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1242—Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
ES01964789T 2000-08-25 2001-08-27 Epitopos de oligosacaridos del nucleo de lipopolisacaridos de maemophilus influenzae como vacunas para la prevencion de infecciones por haemophilus influenzae. Expired - Lifetime ES2284681T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22785000P 2000-08-25 2000-08-25
US227850P 2000-08-25

Publications (1)

Publication Number Publication Date
ES2284681T3 true ES2284681T3 (es) 2007-11-16

Family

ID=22854724

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01964789T Expired - Lifetime ES2284681T3 (es) 2000-08-25 2001-08-27 Epitopos de oligosacaridos del nucleo de lipopolisacaridos de maemophilus influenzae como vacunas para la prevencion de infecciones por haemophilus influenzae.

Country Status (9)

Country Link
US (1) US7364739B2 (enExample)
EP (1) EP1313771B1 (enExample)
JP (1) JP2004506086A (enExample)
AT (1) ATE357461T1 (enExample)
AU (1) AU2001285633A1 (enExample)
CA (1) CA2420477A1 (enExample)
DE (1) DE60127421T8 (enExample)
ES (1) ES2284681T3 (enExample)
WO (1) WO2002016440A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7527797B1 (en) 2000-09-01 2009-05-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vibrio cholerae 0139 conjugate vaccines
HUP0700044A2 (en) 2004-05-14 2009-03-30 Ca Nat Research Council Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates
US8795680B2 (en) * 2006-07-21 2014-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-D-manno-octulsonic acid
JP2008125425A (ja) * 2006-11-20 2008-06-05 Osaka Univ 核酸の増幅反応に用いる繰返し配列結合プライマー及びその利用
CA2680038A1 (en) * 2007-03-08 2008-09-12 The Governors Of The University Of Alberta Bacterial endotoxin for the prevention of metabolic disorders and bacterial infections
WO2016007891A1 (en) * 2014-07-10 2016-01-14 University Of Iowa Research Foundation Vaccine for nontypeable haemophilus influenzae

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0347425B1 (en) 1987-03-02 1995-12-27 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US5204098A (en) * 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
ZA894589B (en) * 1989-02-09 1991-02-27 K Sudan Krishan Semi-flexible or flexible phenolic foam
CA2076753A1 (en) 1990-02-26 1991-08-27 Anthony J. Radford Shuttle plasmid for escherichia coli and mycobacteria
GB9015888D0 (en) 1990-07-19 1990-09-05 Smithkline Biolog Vectors
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
WO1992011361A1 (en) 1990-12-18 1992-07-09 The General Hospital Corporation Improved vaccines
EP0587775A4 (en) 1991-06-06 1994-11-02 Medimmune Inc INDUCTION OF THE CTL RESPONSE BY FOREIGN ANTIGENS EXPRESSED IN MYCOBACTERIES.
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1994016737A1 (en) 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20030072774A1 (en) 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US5527928A (en) * 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
US6207157B1 (en) * 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
DE19844191A1 (de) 1998-09-28 2000-03-30 Pharma Zentrale Gmbh Lipopolysaccharide aus Escherichia coli
DE69926261T2 (de) * 1998-12-15 2006-05-24 Exiqon A/S Koppeln an feste phasen von kohlenhydraten, die von lipopolysacchariden abgeleitet sind
CA2374235A1 (en) 1999-05-18 2000-11-23 University Of Iowa Research Foundation Production of complex carbohydrates

Also Published As

Publication number Publication date
AU2001285633A1 (en) 2002-03-04
EP1313771B1 (en) 2007-03-21
EP1313771A2 (en) 2003-05-28
US7364739B2 (en) 2008-04-29
WO2002016440A8 (en) 2002-11-14
DE60127421T2 (de) 2007-11-29
WO2002016440A9 (en) 2004-05-13
CA2420477A1 (en) 2002-02-28
WO2002016440A3 (en) 2002-06-06
JP2004506086A (ja) 2004-02-26
DE60127421D1 (de) 2007-05-03
WO2002016440A2 (en) 2002-02-28
DE60127421T8 (de) 2008-08-28
US20050153057A1 (en) 2005-07-14
ATE357461T1 (de) 2007-04-15

Similar Documents

Publication Publication Date Title
Behera et al. Total syntheses of conjugation-ready trisaccharide repeating units of Pseudomonas aeruginosa O11 and Staphylococcus aureus type 5 capsular polysaccharide for vaccine development
US5721115A (en) DNA encoding a novel Haemophilus influenzae protein
TWI771663B (zh) E. coli O-抗原多醣生物結合物之製備方法、其組合物及其使用方法
CN113924112A (zh) 大肠杆菌o-抗原多糖的生物缀合物、其生产方法及其使用方法
JP2023539943A (ja) 多価ワクチン組成物及びその使用
EP0565590B1 (en) ADHESIN-OLIGOSACCHARIDE CONJUGATE VACCINE FOR $i(HAEMOPHILUS INFLUENZAE)
US10500262B2 (en) Synthetic antigen constructs against Campylobacter jejuni
EP1313771B1 (en) Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of haemophilus influenzae infections
EP1747262B1 (en) Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates
CN101014698A (zh) 作为多种疫苗候选物的保守性内核脂多糖表位
CN116033941A (zh) 包含合成men a抗原的针对脑膜炎奈瑟氏菌的五价疫苗
JP2004506086A5 (enExample)
US10500261B2 (en) Synthetic antigen constructs against campylobacter jejuni
KR20240161137A (ko) 녹농균 감염의 예방/치료
HK40113822A (zh) 预防/治疗铜绿假单胞菌感染
KR20070031936A (ko) 다종 백신 후보로서의 보존된 내부 코어 지질다당류에피토프
EA046636B1 (ru) Способы получения биоконъюгатов полисахаридных о-антигенов e. coli, их композиции и способы их применения
EA046206B1 (ru) Биоконъюгаты полисахаридных о-антигенов e.coli, способы их получения и способы их применения
Kamerling Potential synthetic carbohydrate-protein conjugate vaccines against Streptococcus pneumoniae serotypes